Krystal Biotech, Inc. $KRYS Shares Sold by Vestor Capital LLC

Vestor Capital LLC cut its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 93.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 200 shares of the company’s stock after selling 2,740 shares during the quarter. Vestor Capital LLC’s holdings in Krystal Biotech were worth $52,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of KRYS. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the first quarter valued at approximately $34,000. Bank of America Corp DE grew its stake in Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after acquiring an additional 69,840 shares during the period. Janus Henderson Group PLC grew its stake in Krystal Biotech by 21.5% in the 1st quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock worth $68,879,000 after acquiring an additional 47,219 shares during the period. Cim LLC acquired a new position in Krystal Biotech in the 1st quarter valued at $3,872,000. Finally, Amundi raised its holdings in Krystal Biotech by 52.0% in the 1st quarter. Amundi now owns 5,706 shares of the company’s stock valued at $1,474,000 after acquiring an additional 1,952 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock worth $8,243,923 in the last quarter. 13.10% of the stock is owned by insiders.

Krystal Biotech Stock Down 7.0%

Shares of KRYS opened at $341.12 on Friday. The firm has a market cap of $10.06 billion, a PE ratio of 45.60 and a beta of 0.50. The company’s fifty day moving average is $339.70 and its two-hundred day moving average is $296.28. Krystal Biotech, Inc. has a fifty-two week low of $130.50 and a fifty-two week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KRYS shares. Jefferies Financial Group restated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Bank of America upped their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. HC Wainwright raised their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Finally, Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.